| Identifying medication targets for psychostimulant addiction: unraveling the dopamine D3 receptor hypothesis TM Keck, WS John, PW Czoty, MA Nader, AH Newman Journal of medicinal chemistry 58 (14), 5361-5380, 2015 | 110 | 2015 |
| Interferon regulatory factor 3 is necessary for induction of antiviral genes during human cytomegalovirus infection VR DeFilippis, B Robinson, TM Keck, SG Hansen, JA Nelson, KJ Früh Journal of virology 80 (2), 1032-1037, 2006 | 95 | 2006 |
| Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid … V Kumar, A Bonifazi, MP Ellenberger, TM Keck, E Pommier, R Rais, ... Journal of medicinal chemistry 59 (16), 7634-7650, 2016 | 90 | 2016 |
| High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice CA Boateng, OM Bakare, J Zhan, AK Banala, C Burzynski, E Pommier, ... Journal of medicinal chemistry 58 (15), 6195-6213, 2015 | 57 | 2015 |
| Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D3 Receptor Antagonists J Chen, B Levant, C Jiang, TM Keck, AH Newman, S Wang Journal of Medicinal Chemistry 57 (11), 4962-4968, 2014 | 55 | 2014 |
| Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor M Michino, CA Boateng, P Donthamsetti, H Yano, OM Bakare, A Bonifazi, ... Journal of medicinal chemistry 60 (2), 580-593, 2017 | 52 | 2017 |
| K+ channel KV3. 1 associates with OSP/claudin-11 and regulates oligodendrocyte development S Tiwari-Woodruff, L Beltran-Parrazal, A Charles, T Keck, T Vu, ... American Journal of Physiology-Cell Physiology, 2006 | 51 | 2006 |
| Synthesis and pharmacological characterization of novel trans-cyclopropylmethyl-linked bivalent ligands that exhibit selectivity and allosteric pharmacology at the dopamine D3 … V Kumar, AE Moritz, TM Keck, A Bonifazi, MP Ellenberger, CD Sibley, ... Journal of medicinal chemistry 60 (4), 1478-1494, 2017 | 48 | 2017 |
| Beyond Small-Molecule SAR: Using the Dopamine D3 Receptor Crystal Structure to Guide Drug Design. TM Keck, C Burzynski, L Shi, AH Newman Advances in pharmacology (San Diego, Calif.) 69, 267-300, 2014 | 47 | 2014 |
| A novel mGluR5 antagonist, MFZ 10‐7, inhibits cocaine‐taking and cocaine‐seeking behavior in rats TM Keck, MF Zou, GH Bi, HY Zhang, XF Wang, HJ Yang, R Srivastava, ... Addiction Biology 19 (2), 195-209, 2014 | 46 | 2014 |
| Fenobam sulfate inhibits cocaine-taking and cocaine-seeking behavior in rats: implications for addiction treatment in humans TM Keck, HJ Yang, GH Bi, Y Huang, HY Zhang, R Srivastava, EL Gardner, ... Psychopharmacology 229 (2), 253-65, 2013 | 39 | 2013 |
| Novel Analogues of (R)-5-(Methylamino)-5, 6-dihydro-4 H-imidazo [4, 5, 1-ij] quinolin-2 (1 H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity M Zou, TM Keck, V Kumar, P Donthamsetti, M Michino, C Burzynski, ... | 36 | 2016 |
| Using click chemistry toward novel 1, 2, 3-triazole-linked dopamine D3 receptor ligands TM Keck, AK Banala, RD Slack, C Burzynski, A Bonifazi, ... Bioorganic & medicinal chemistry 23 (14), 4000-4012, 2015 | 35 | 2015 |
| Dopamine D4 receptor deficiency in mice alters behavioral responses to anxiogenic stimuli and the psychostimulant methylphenidate TM Keck, KL Suchland, CC Jimenez, DK Grandy Pharmacology Biochemistry and Behavior 103 (4), 831–841, 2013 | 31 | 2013 |
| Dopamine D4 Receptor-Selective Compounds Reveal Structure–Activity Relationships that Engender Agonist Efficacy TM Keck, RB Free, MM Day, SL Brown, MS Maddaluna, G Fountain, ... Journal of medicinal chemistry 62 (7), 3722-3740, 2019 | 30 | 2019 |
| The replacement of the 2-methoxy substituent of N-((6, 6-diphenyl-1, 4-dioxan-2-yl) methyl)-2-(2-methoxyphenoxy) ethan-1-amine improves the selectivity for 5-HT1A receptor over … F Del Bello, A Bonifazi, M Giannella, G Giorgioni, A Piergentili, R Petrelli, ... European Journal of Medicinal Chemistry 125, 233-244, 2017 | 18 | 2017 |
| Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist AE Moritz, RB Free, WS Weiner, EO Akano, D Gandhi, A Abramyan, ... Journal of medicinal chemistry 63 (10), 5526-5567, 2020 | 17 | 2020 |
| Metabotropic glutamate receptor 5 negative allosteric modulators as novel tools for in vivo investigation TM Keck, MF Zou, P Zhang, RP Rutledge, AH Newman ACS medicinal chemistry letters 3 (7), 544-549, 2012 | 17 | 2012 |
| Neurochemical and behavioral comparisons of contingent and non-contingent methamphetamine exposure following binge or yoked long-access self-administration paradigms CA Schweppe, C Burzynski, S Jayanthi, B Ladenheim, JL Cadet, ... Psychopharmacology 237, 1989-2005, 2020 | 16 | 2020 |
| Multitarget 1,4-Dioxane Compounds Combining Favorable D2-like and 5-HT1A Receptor Interactions with Potential for the Treatment of Parkinson’s Disease or … F Del Bello, D Ambrosini, A Bonifazi, AH Newman, TM Keck, M Giannella, ... ACS chemical neuroscience 10 (5), 2222-2228, 2019 | 15 | 2019 |
Newman Amy HauckNational Institue on Drug Abuse-Intramural Research Program, NIHПідтверджена електронна адреса в intra.nida.nih.gov
